This Article Full Text Full Text (PDF) All Versions of this Article: 92/11/4218    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fazio, S. Articles by Saccà, L. Search for Related Content PubMed PubMed Citation Articles by Fazio, S. Articles by Saccà, L. Related Collections Cardiovascular Endocrinology Neuroendocrinology and Pituitary

Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients with Chronic Heart Failure

Department of Internal Medicine, Cardiovascular and Immunological Sciences, University Federico II School of Medicine, 80131 Naples, Italy

Address all correspondence and requests for reprints to: Serafino Fazio, III Medicina Interna, Via S. Pansini, 5, 80131 Napoli, Italy. E-mail: fazio{at}unina.it.

Background: Because GH exerted beneficial effects in various experimental models of heart failure, we investigated the effects of GH on physical exercise capacity and cardiopulmonary performance in patients with dilated cardiomyopathy and chronic heart failure (CHF).

Methods: Twenty-two patients with CHF (New York Heart Association functional class II-III) underwent spirometry and a symptom-limited, cardiopulmonary exercise testing before and after 3 months of GH (n = 11; seven males; seven idiopathic; 57 ± 11 yr; 4 IU sc every other day) or placebo (n = 11; eight males; six idiopathic; 54 ± 10 yr) administration, in a randomized, double-blind trial. Background CHF therapy remained unchanged.

Results: GH, but not placebo, increased IGF-I serum concentration (from 144 ± 35 to 293 ± 58 ng/ml; P < 0.005) and improved New York Heart Association functional class (from 2.4 ± 0.5 to 1.8 ± 0.4; P < 0.005), exercise duration (from 831 ± 273 to 925 ± 266 sec; P < 0.005), peak power output (from 245 ± 127 to 280 ± 132 W; P < 0.05), peak minute ventilation (from 52.5 ± 16.1 to 61.3 ± 17.3 liters/min; P < 0.05), peak oxygen consumption (from 19.8 ± 5.6 to 25.1 ± 5.6 ml/kg·min; P < 0.005), and anaerobic threshold (from 14.9 ± 4.8 to 20.0 ± 4.5 ml/kg·min; P < 0.005) without affecting lung function parameters. Furthermore, the slope of the relationship between minute ventilation and pulmonary carbon dioxide production (ventilatory efficiency) decreased from 34.7 ± 5.1 to 31.7 ± 5.3 (P < 0.005), whereas the slope of the relation between percent predicted heart rate reserve used and percent observed metabolic reserve used (chronotropic index) rose from 0.57 ± 0.20 to 0.69 ± 0.18 (P < 0.005).

Conclusion: Given the predictive value of physical exercise capacity and cardiopulmonary performance in CHF progression, these data provide additional insights into the mechanisms by which GH may potentially benefit CHF patients.

This article has been cited by other articles:

				J. A. Hill and E. N. Olson Cardiac Plasticity N. Engl. J. Med., March 27, 2008; 358(13): 1370 - 1380. [Full Text] [PDF]